Administering the HPV Vaccine to People Living with HIV: Providers’ Perspectives
| Autor: | Stephanie Brennhofer, Alexis Koskan, Deborah L. Helitzer |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Health Personnel HIV Infections Disease 03 medical and health sciences Acquired immunodeficiency syndrome (AIDS) Health care Humans Medicine Anal cancer 0501 psychology and cognitive sciences Papillomavirus Vaccines Qualitative Research Aged 030505 public health business.industry Public health 05 social sciences Public Health Environmental and Occupational Health virus diseases Middle Aged Patient Acceptance of Health Care Anus Neoplasms medicine.disease Vaccination Health psychology Family medicine Female 0305 other medical science business 050104 developmental & child psychology Qualitative research |
| Zdroj: | The Journal of Primary Prevention. 41:349-362 |
| ISSN: | 1573-6547 0278-095X |
| Popis: | HIV-positive patients suffer disproportionate burden of anal cancer, a disease which is primarily caused by persistent infection with human papillomavirus (HPV) and is potentially preventable with the completion of the HPV vaccine series. Past research qualitatively explored HIV-positive patients' perspectives about the HPV vaccine. However, little is known about their healthcare practitioners' vaccine recommendation behaviors, the strongest influence on vaccine uptake. This study reports on in-depth interviews conducted with 25 healthcare practitioners who provide care for HIV-positive patients. Qualitative themes that emerged from the study included clinicians' HPV vaccination behaviors, HIV patient's willingness to get the HPV vaccine, the role of HIV-positive patients' immune functioning in terms of timing of HPV vaccine administration, and vaccinating HIV-positive patients over age 26. The majority of providers offered the vaccine at their healthcare facility. Participants varied in their opinions related to the importance of patients' CD4 count in terms of timing of HPV vaccine administration; some believed that patients' immune functioning should first be stabilized to receive the most benefit from the vaccine series. They also differed in the perceived benefit of offering the vaccine to patients over age 26. In light of the U.S. Food and Drug Administration's recent approval to extend HPV vaccination to adults up to age 45 years, more HIV-positive adults may benefit by receiving this vaccine series. Future efforts should ensure that providers regularly promote the HPV vaccine to their adult HIV-positive patients. Vaccinating HIV-positive patients may help reduce the burden of HPV-related cancers, particularly anal cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink